Page 19 - Regarding Use News Today

Jaguar Health, Inc. Reports 2021 First Quarter Financial Results ACCESSWIRE 17 May 2021, 22:05 GMT+10 First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar or the Company) today...

Halozyme Reports First Quarter 2021 Results - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 - - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 - - Reiterate 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue - - Reiterate 2021 GAAP Operating Income Guidance of $215 million to $235 million, Representing 49%-63% Growth over 2020 GAAP Opera...

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced... | May 5, 2021

Search jobs Glaukos Corporation Announces First Quarter 2021 Financial Results SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include: Net sales growth of 23% to $68.0 million in Q1 2021, compared ...

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r M...

-- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million -- -- First-Quarter 2021 Orphan Segment Net Sales Increased

Share this article Share this article NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three-month period ended March 31, 2021. Jerrell Shelton, CEO of Cryoport, said, "It was a strong quarter and it developed as we had anticipated. We entered 2021 with an unrivaled leadership position with market...

Operating adjusted EBITDA Investment gains Completed acquisition of National Holdings, enhancing wealth management and capital markets Declared total quarterly dividend of $3.00 per common share Bryant Riley, Chairman and Co-Chief Executive Officer of B. Riley Financial, said: "Our first quarter performance again demonstrates the combined platforms strength and earnings power, with this period driven by particularly exceptional results from our investment banking group. Our results were enhan...

Posted April 16th, 2021 for TD Bank TORONTO , April 16, 2021 /CNW/ - TD Bank Group (the "Bank") announced today that it expects The Charles Schwab Corporations ("Schwab") first quarter earnings to translate into approximately CDN $223 million of reported equity in net income of an investment in Schwab for the Banks fiscal 2021 second quarter. Excluding acquisition-related charges of approximately CDN $15 million after-tax and amortization of acquired intangibles of approximately CD...

  See reconciliations of these non-GAAP measurements to the most directly comparable GAAP measures included in the financial tables. See also “Note Regarding Use of Non-GAAP Financial Measurements” below for the definitions of these non-GAAP measures. The Company continues to evaluate the global risks and the slowdown in business activity related to COVID-19, including the potential impacts on its employees, customers, suppliers and financial results. The severity of the impact on the Comp...